Based on the L&G Pharma Breakthrough UCITS ETF stock forecast from 0 analysts, the average analyst target price for L&G Pharma Breakthrough UCITS ETF is not available over the next 12 months. L&G Pharma Breakthrough UCITS ETF’s average analyst rating is not available. Stock Target Advisor’s own stock analysis of L&G Pharma Breakthrough UCITS ETF is Very Bearish, which is based on 0 positive signals and 3 negative signals. At the last closing, L&G Pharma Breakthrough UCITS ETF’s stock price was EUR 9.53. L&G Pharma Breakthrough UCITS ETF’s stock price has changed by -1.31% over the past week, -4.33% over the past month and +1.58% over the last year.
Analyst Ratings
Target Price Action
Rating Action
Analyst
Rating
Price
Date
Stock Target Advisor's Analysis
This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.
What to like
There is nothing we particularly like
What not to like
Below median dividend returns
The company’s average income yield over the past 5 years has been low compared to its peers. However, it is not a problem if you are not looking for income.
Poor risk adjusted returns
This company is delivering below median risk adjusted returns in its peers. Even if it is outperforming on returns , the returns are unpredictable. Proceed with caution.
Low market capitalization
This is among the smaller entities in its sectors with below median market capitalization. That may make it less stable in the long run unless it has a unique technology or market which can help it grow or get acquired in future.
Add to Watchlists
loading..
Download Confirmation
Premium customers can only download records visible on the current page view, while Platinum customers can download the first 1000 records.
Paid-only feature
CSV downloads are only available for paying customers.
Thank you for Sharing your Stock Targets for ETLI:XETRA !
Loading...
Please login to proceed
Sorry - extended search is only available for registered users.
